Fierce Pharma

SEPTEMBER 16, 2024

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. | Looking to assess whether Ocaliva met its postmarketing requirements after a 2016 accelerated approval in the autoimmune disease primary biliary cholangitis, an FDA council of outside experts nearly unanimously rejected Intercept’s hopes for a full approval.

FDA 264

FDA 264

Authentic Influence Group

SEPTEMBER 16, 2024

The Silent Edge: How Body Language and Communication Skills Shape Leadership Success October 9, 2024 | 8:00 AM | NYC Free Event | Limited to 30 Seats Enjoy a Breakfast Bagel | Take in the NYC Skyline | Master Leadership Through Body Language Harness the power of what’s not being said. Join Shelly O’Donovan to master body language that transforms your leadership presence, influences decisions, and builds stronger teams.

Consulting 130

Consulting Competition Training Leads 130

Fierce Pharma

SEPTEMBER 16, 2024

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. | Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U.S. regulator has signed off on IL-13 inhibitor Ebglyss, or lebrikizumab, to treat atopic dermatitis.

FDA 246

FDA 246

MedCity News

SEPTEMBER 16, 2024

It’s important that we focus attention on the areas where AI is already having a significant impact. These are the practical applications that will allow the best and brightest researchers to focus on science rather than data munging. The post We’re Overcomplicating Healthcare AI — Here’s How We Achieve Impact Beyond The Hype appeared first on MedCity News.

Healthcare 127

Healthcare Healthcare Electronics Medical 127

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

SEPTEMBER 16, 2024

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between Exelixis and its partner Ipsen. | The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between Exelixis and its partner Ipsen.

FDA 230

FDA 230

MedCity News

SEPTEMBER 16, 2024

Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020. The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News.

Competition 126

Competition Pharma FDA Biopharma 126

Pharmaceutical Technology

SEPTEMBER 16, 2024

While Lykos Therapeutics’ MDMA therapy was rejected by the FDA, psychedelic therapy advocates remain optimistic about the sector.

FDA 119

FDA 119

pharmaphorum

SEPTEMBER 16, 2024

FDA raps AbbVie for 'misleading' ad for migraine drug Ubrelvy featuring tennis star Serena Williams

FDA 119

FDA 119

MedCity News

SEPTEMBER 16, 2024

Providence Health Plan and the American Heart Association will create blood pressure programs in 20 community organizations and clinics over three years. The post Providence Health Plan, American Heart Association Launch Cardiovascular Health Initiative appeared first on MedCity News.

119

119

pharmaphorum

SEPTEMBER 16, 2024

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia in a phase 2 trial presented at ESMO

Patients 114

Patients 114

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

SEPTEMBER 16, 2024

Pediatric innovation in mental health is the theme of the INVEST Digital Health Pitch Perfect contest at Pegasus Park in Dallas on September 18. The post Where is Pediatric Innovation Making an Impact? appeared first on MedCity News.

116

116

pharmaphorum

SEPTEMBER 16, 2024

AstraZeneca reveals 'practice changing' data for Imfinzi as peri-operative therapy for bladder cancer, but will the FDA accept the study?

FDA 111

FDA 111

MedCity News

SEPTEMBER 16, 2024

This test can be thought of as a crystal ball for cancer survivors and research has found it can predict with near certainty whether a patient’s cancer will recur. So why aren’t more patients getting the test? The post A Crystal Ball for Cancer Survivors appeared first on MedCity News.

Patients 113

Patients 113

pharmaphorum

SEPTEMBER 16, 2024

Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.A new partnership has been set up between the Ella Dawson Foundation, a UK-based charity for young people with cancer, and digital cancer care company Careology to try to tackle that deficit and improve their treatment and wellbeing.

Patients 105

Patients 105

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

PharmaTimes

SEPTEMBER 16, 2024

The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex

101

101

Pharmaceutical Technology

SEPTEMBER 16, 2024

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

98

98

PharmaVoice

SEPTEMBER 16, 2024

Five ways to beat study timeline pressures and get medicines to patients faster.

Medicine 94

Medicine Patients 94

Pharmaceutical Technology

SEPTEMBER 16, 2024

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12.

FDA 98

FDA Patients 98

Advertisement

pharmaphorum

SEPTEMBER 16, 2024

J&J plans phase 3 trials for Rybrevant in colorectal cancer, after reporting positive results for the METxEGFR bispecific antibody at ESMO

91

91

Pharmaceutical Technology

SEPTEMBER 16, 2024

Roche has secured approval from the US Food and Drug Administration for Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology.

Food and Drug Administration 95

Food and Drug Administration Food FDA 95

pharmaphorum

SEPTEMBER 16, 2024

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back on track.Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category but picked up its first approval in the rare tumour Merkel cell carcinoma last year.

FDA 88

FDA 88

MedCity News

SEPTEMBER 16, 2024

MIT spinout Bloomer Tech is developing a wearable electrocardiogram device designed to look and feel like a bra. The post Not Your Average Bra: How Bloomer Tech’s Wearable Is Addressing Heart Disease in Women appeared first on MedCity News.

69

69

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

PharmaVoice

SEPTEMBER 16, 2024

After the House of Representatives passed the Biosecure Act last week, U.S. biotechs could be forced to cut ties with five Chinese contract partners.

Biopharma 64

Biopharma 64

Pharmaceutical Commerce

SEPTEMBER 16, 2024

The manufacturing line producing the company’s branded form of nirsevimab-alip has been approved by the FDA.

Manufacturing 59

Manufacturing FDA 59

PharmaVoice

SEPTEMBER 16, 2024

Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.

59

59

Pharmacy Times

SEPTEMBER 16, 2024

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Patients 52

Patients 52

Advertisement

Distribution

Pharmaceutical Technology

SEPTEMBER 16, 2024

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

52

52

PharmExec

SEPTEMBER 16, 2024

Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.

FDA 52

FDA Patients 52

Pharmaceutical Technology

SEPTEMBER 16, 2024

As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying therapies.

52

52

PharmExec

SEPTEMBER 16, 2024

Ocrevus Zunovo is the first and only twice-yearly, 10-minute subcutaneous injection for treating both relapsing multiple sclerosis and primary-progressive multiple sclerosis.

FDA 52

FDA 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales